Asian Journal of Immunology

Conceptual Framework and Strategy for Designing Population-specific Epitope-based HIV-1 CTL Vaccine- a Proposal for the Nigerian Population

Samuel Adinoyi Adavba *

Kaduna State University, Kaduna, Nigeria.

*Author to whom correspondence should be addressed.

---

Abstract

HIV infection has remained a global health concern since its discovery over forty years ago. Although antiretroviral (ARV) drugs have changed the initial damning prognosis, the need to prevent new infection is still as pressing as ever because individuals who have achieved viral suppression on Antiretroviral therapy have an additional concern of increased susceptibility to non-AIDS-defining illnesses compared to the general population. This is attributable to the progressive immunological dysfunction in these individuals, a pathology that current therapeutic options for HIV management cannot ameliorate. Vaccination, which is the game-changing intervention for most communicable diseases, is constrained by the peculiar molecular bottleneck created by HIV hypermutability, making vaccine development quite challenging. This article reviews the dynamics of these challenges and makes a case for a customized vaccine development approach that leverages the insights gained from the HLA profiles of the HIV elite controllers. It then suggests a conceptual framework for developing a population-based CTL epitope-based HIV-1 vaccine using the Nigerian population as a model. 

Keywords: HIV-1 vaccine, human leucocyte antigen (HLA), genetic diversity, epitope-based vaccine

---

---

---

References

Fields BN, Knipe DM, Howley PM. Fields' virology (5th ed.). Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007.

Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med. 2004;10(8):806-10. DOI 10.1038/nm0804-806. PMID: 15286782.

Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401-9. DOI: 10.1086/589862. PMID: 18558875.

Sun Z.Y, Oh KJ, Kim M, Yu J, Brusic V, Song L, Qiao Z, Wang JH, Wagner G, Reinherz EL. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008;28:52–63

Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci 2008;105:3739–3744

Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001;(58):19–42.

Esbjörnsson J, Månsson F, Martínez-Arias W, Vincic E, Biague AJ, da Silva ZJ, Fenyö EM, Norrgren H, Medstrand P. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease-an indication of an evolving epidemic in West Africa. Retrovirology. 2010;7: 23. Available:https://doi.org/10.1186/1742-4690-7-23

Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol. 2010; 28:413-44. DOI: 10.1146/annurev-immunol-030409-101256. PMID: 20192810

Abecasis et al. HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology. 2013;7(10)

Tongo M, Dorfman JR, Martin DPHigh Degree of HIV-1 Group M (HIV-1M) Genetic Diversity within Circulating Recombinant Forms: Insight into the Early Events of HIV-1M Evolution. Journal of Virology. 2015;90(5):2221–2229. Available:https://doi.org/10.1128/JVI.02302-15

Ajoge HO, Gordon ML, de Oliveira T, Green TN, Ibrahim S. et al. Genetic Characteristics, Co-receptor Usage Potential and Evolution of Nigerian HIV-1 Subtype G and CRF02_AG Isolates. PLoS ONE 2011 6(3):

Njoku OS, Manak MM, O’Connell RJ, Shutt ALW, Malia JA, et al. An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria. PLOS ONE. 2016;11(12).

Stephenson KE, Barouch DH. A global approach to HIV-1 vaccine development. Immunological Reviews. 2013;254(1):295–304. Available:https://doi.org/10.1111/imr.12073

Winkler C, An P, O'Brien SJ. Patterns of ethnic diversity among the genes that influence AIDS. Hum Mol Genet. 2004;13(1):9-19. Doi: 10.1093/hmg/ddh075. Epub PMID: 14764621.

Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, et al. A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. Science, 2007;317(944)

Aziz N, Jamieson BD, Quint JJ, Martinez-Maza O, Chow M, Detels R. Longitudinal Intra- and Inter-individual variation in T-cell subsets of HIV-infected and uninfected men participating in the LA Multi-Center AIDS Cohort Study. Medicine. 2019;98(41):e17525. Available:https://doi.org/10.1097/MD.0000000000017525

Modi WS, Lautenberger J, An P. et al. Genetic variation in the CCL18-CCL3-CCL4 chemokine gene cluster influences HIV type 1 transmission and AIDS disease progression. Am J Hum Genet: 2006; 79:120–8.

Kaur G. Mehra N. Genetic determinants of HIV-1 infection and progression to AIDS: susceptibility to HIV infection. Tissue Antigens. 2007;(73):289–301.

Baker BM, Block BL, Rothchild A, Walker BD. Elite control of HIV infection: implications for vaccines and treatments. Expert Opin Biol Ther. 2009; 9:55–69.

Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, Burgett N, Swartz ME, Yang A, Alter G, Yu XG, Meier A, Rockstroh JK, Allen TM, Jessen H, Rosenberg ES, Carrington M, Walker BD. HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8+ T Cell Response against HIV-1. PLoS Medicine. 2006;3(10). Available:https://doi.org/10.1371/journal.pmed.0030403

Tang J, Tang S, Lobashevsky E. Myracle AD, Fideli U, Aldrovandi G, Allen S, Musonda R, Kaslow RA. Favourable and Unfavorable HLA Class I Alleles and Haplotypes in Zambians Predominantly Infected with Clade C Human Immunodeficiency Virus Type 1. Journal of Virology, 2002;76(16):8276-8284. Available:https://doi.org/10.1128/JVI.76.16.8276-8284.2002

Carrington M et al. HLA and HIV-1 Heterozygote advantage and B*35-Cw*04 disadvantage. Science, 1999;283:1748–1752.

Lunardi LW, Bragatte MADS, Vieira G.F. The influence of HLA/HIV genetics on the occurrence of elite controllers and a need for therapeutics geotargeting view. The Brazilian Journal of Infectious Diseases. 2021;25(5):101619. Available:https://doi.org/10.1016/j.bjid.2021.101619

Rihn SJ, Wilson SJ, Loman NJ, Alim M, Bakker SE, et al. Extreme Genetic Fragility of the HIV-1 Capsid. PLoS Pathog. 2013:9(6)

Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunology. 2008;8:619-630.

Tang J. et al. HLA class I homozygosity accelerates disease progression in HIV-1 infection. AIDS Res Human Retroviruses1999;(15)317–324

Garcia V, Regoes RR. The Effect of Interference on the CD8+ T Cell Escape Rates in HIV. Frontiers in Immunology. 2015;5:121660. Available:https://doi.org/10.3389/fimmu.2014.00661

Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Current opinion in HIV and AIDS, 2019 14(3):153–160. Available:https://doi.org/10.1097/COH.0000000000000534

Moise L, Gutierrez A, Kibria F, Martin R, Tassone R, Liu R, Terry F, Martin B, De Groot AS. IVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines. Human Vaccines & Immunotherapeutics. 2015;11(9):2312-2321.

Available:https://doi.org/10.1080/21645515.2015.1061159

Toussaint NC, Dönnes P, Kohlbacher O. A Mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines. PLoS Comput Biol 2008;4(12):e1000246 Available:https://doi.org/10.1371/journal.pcbi.1000246

Goulder P, Walker B. HIV and HLA class I: An evolving relationship. Immunity. 2012;(37)426–440.

Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197(4):563-571. DOI:10.1086/526786

Mahiti M, Toyoda M, Jia X, et al. Relative Resistance of HLA-B to Downregulation by Naturally Occurring HIV-1 Nef Sequences. mBio. 2016;7(1):e01516-15. Published 2016 Jan 19. doi:10.1128/mBio.01516-15